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Essentials
• Choice of anticoagulant therapy in thrombosis in unusual locations remains controversial.
• Guideline lines on this topic are discordant.
• Clinical practice is heterogeneous with regard to choice of drug class and duration of treatment.
• Randomized controlled trials applying functional outcome and quality of life as important outcomes are urgently needed.
A large number of studies have focused on venous thromboem-
bolism (VTE) over the past decades, accumulating to a staggering 
23 595 articles indexed in Medline (August 3, 2020). Perhaps as a 
consequence of these efforts, mortality of VTE has decreased over 
time.1 Despite this success, many aspects of the optimal care for 
patients at risk for or diagnosed with VTE remain uncertain. One 
of the topics for which current evidence falls short to support any 
strong-level recommendation is the management of thromboses at 
unusual locations, such as splanchnic vein thrombosis and cerebral 
vein thrombosis.
Reasons for the lack of adequately sized randomized studies on 
this particular topic are its relative rarity, at least if compared with 
“usual” VTE, as well as logistical issues related to the complexity (and 
heterogeneity) of the clinical scenarios in which thrombosis at un-
usual locations occurs. For instance, splanchnic vein thrombosis is 
often associated with liver cirrhosis, bacterial infections, and cancer, 
conditions that are intrinsically associated with a substantial risk of 
anticoagulant treatment–associated bleeding.2,3 Moreover, patients 
suffering from thromboses at unusual locations may not always be 
ideal candidates for participating in clinical trials in relation to usual 
eligibility criteria, including a long life expectancy, good adherence 
to the study procedures, and lack of contraindications to specific an-
ticoagulant agents. In some cases, these patients are simply unable 
to consent to participation.
As a consequence, practice guidelines base their recommenda-
tions on available evidence from retrospective cohorts studies and 
extrapolation from interventional studies of deep vein thrombo-
sis (DVT) and acute pulmonary embolism (PE).4-6 The latter makes 
sense considering some shared pathophysiological mechanisms of 
thrombus formation but may diverge considering the ultimate goal 
of treatment. For DVT and PE, this is prevention of recurrent VTE, 
thrombus propagation, and progression to potentially fatal PE. This 
is less relevant for thromboses at unusual sites since splanchnic 
vein thrombosis and cerebral vein thrombosis do not progress to 
acute PE. Instead, the main goal of treating thromboses at unusual 
locations—in addition to prevention of extension or recurrence—is 
prevention of local infarction, venous hypertension with associated 
(bleeding) complications, and organ dysfunction.
Large randomized trials have undoubtedly demonstrated the bet-
ter safety profile of oral direct anticoagulants (DOACs) over vitamin K 
antagonists (VKAs) when it comes to the treatment of DVT and acute 
PE.7 The applicability of these findings for the choice of anticoagulant 
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therapy for patients with thromboses at unusual locations is still debat-
able. Arguments used to promote or warn for the use of DOACs in this 
setting include the overall safety profile of anticoagulant drug classes, 
relevance of a first-pass effect in the portal circulation of selected 
DOACs, the ability to reverse the anticoagulant in case of major bleed-
ing, the potential presence (or risk) of relevant liver/renal dysfunction, 
the possibility to monitor anticoagulation intensity, the preference for 
oral over parenteral drugs, costs, availability, off-label status, and the 
absence of high-level evidence. As is often the case in areas of such 
uncertainty, recent guidelines provide conflicting recommendations, 
causing considerable heterogeneity in global treatment patterns.4-6 
The European Stroke Organization, for instance, recommends against 
the use of DOACs for the treatment of cerebral vein thrombosis.4 
The American College of Gastroenterology suggests using low-mo-
lecular-weight heparin (LMWH) and VKAs over DOACs for the initial 
and chronic treatment of splanchnic vein thrombosis.5 In contrast, 
the ISTH Scientific and Standardization Committee (SSC) Control of 
Anticoagulation subcommittee suggests prescribing a DOAC at full 
dose over conventional anticoagulation, albeit only in noncirrhotic pa-
tients, with adequate renal function and without luminal gastrointes-
tinal cancer and/or contraindications for the use of DOACs.6 Notably, 
in our view, a preference for either of the available drug classes in pa-
tients with splanchnic vein thromboses and cerebral vein thromboses 
is surprising considering the minimal low-quality data available.
In this issue of Research and Practice in Thrombosis and 
Haemostasis, Nicoletta Riva and colleagues illustrate the status quo 
of treatment of thrombosis at unusual locations. They performed a 
cross-sectional survey among physicians, consisting of four vignette 
cases with either provoked or unprovoked splanchnic or cerebral 
vein thrombosis. Participants were asked to detail their preferred 
therapeutic approach in each of these vignettes: choice of drug, 
drug dose, and duration of treatment, including a rationale for the 
chosen treatment. The main findings of the study may be summa-
rized as follows: (i) wide variability in all aspects of the treatment, 
(ii) DOACs were considered in all four vignettes, but (iii) the majority 
of responders preferred conventional anticoagulation over DOACs 
across all scenarios. In the vignettes with a clear provoked throm-
bosis, 23% and 28% of responders indicated to consider treatment 
with a DOAC. In the vignettes with the highest perceived risk of 
bleeding, this was only 9%–10%, respectively. Suggested duration 
of anticoagulant treatment also considerably differed in all four vi-
gnettes, without a clear common preference.
What does this important study tell us? First and foremost, it un-
derlines the urgent need of performing properly designed randomized 
trials comparing the available therapeutic approaches, despite the 
foreseen efforts in the author’s conduction. The formal outcomes of 
such studies should ideally go beyond mortality, recurrent VTE, major 
bleeding, and ischemic complications, also accounting for functional 
outcomes, quality of life, and patient satisfaction (Figure 1). Given the 
substantial equivalence of DOACs and heparin/VKAs concerning the 
net clinical outcome of recurrence plus bleeding, it is more likely that 
such patient-relevant functional outcomes may reflect differences in 
administration, monitoring, and drug-specific complications of an anti-
coagulant strategy over the other.8 This may also allow the conduction 
of pharmacoeconomic analyses. Second, the results of the study will 
definitely shape future discussions on this topic and contribute to de-
signing the optimal trial to provide the relevant evidence required for 
strong and consistent guideline recommendations.
What is to be done in our daily practice until the results of such 
studies are available? In this more or less evidence-free zone, expe-
rience does count for something. Taking the paucity of comparative 
studies and the off-label status of DOACs into account, as well as the 
long but relevant list of “ifs and buts” as stated in the SSC recom-
mendation,6 we feel strengthened by the results of the survey to be 
restrictive in the use of DOACs as primary treatment of splanchnic and 
cerebral vein thrombosis and consider DOACs only as an alternative to 
conventional treatment in selected cases without contraindications to 
the use of DOACs, rather than as preferred management.
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